PMID- 17587181
OWN - NLM
STAT- MEDLINE
DCOM- 20070913
LR  - 20191210
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 104
IP  - 1
DP  - 2007 Jul
TI  - Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy 
      specimens in determining HER2 as a prognosticator in locally advanced breast 
      cancer.
PG  - 31-7
AB  - PURPOSE: We evaluated the clinical significance of HER2 in post-chemotherapy 
      specimens after surgery in locally advanced breast cancer (LABC). METHODS: 
      Thirty-four patients with LABC were treated with neoadjuvant chemotherapy, 
      surgery, adjuvant chemotherapy, and radiotherapy. The HER2 status was determined 
      using both immunohistochemistry (IHC) and fluorescence in situ hybridization 
      (FISH) in the paraffin-embedded surgical specimens after neoadjuvant 
      chemotherapy. RESULTS: The positive rate of HER2 was 41.2% and 32.4% by IHC and 
      FISH, respectively. As the gene copy number of HER2 detected by FISH increased, 
      the staining intensity by IHC increased with positive correlation (adjusted r (2) 
      = 0.743; P < 0.001). According to the cutoff values of IHC score 2+ and 3+ as the 
      positivity criteria, the concordance rates of IHC and FISH were 91.2% (31/34) and 
      88.2% (30/34), respectively. With the positivity criteria of IHC score > or =2+, 
      the locoregional recurrence-free survival was better in the HER2-negative 
      patients (P = 0.04). Trends were also found for the prolonged distant 
      recurrence-free, disease-free, and overall survivals in the HER2-negative 
      patients by IHC (2+). Trends for poor clinical response (P = 0.06) and more 
      axillary nodes involvement (P = 0.08) were noted in the HER2-positive group by 
      IHC (2+). In post-chemotherapy specimens, the positive HER2 status by IHC 
      staining score > or = 2+ predicted higher recurrence in LABC. CONCLUSION: This 
      suggests that different criteria for the HER2 positivity by IHC can be applied in 
      post-chemotherapy specimens compared with that from pre-chemotherapy biopsies.
FAU - Moon, Yong Wha
AU  - Moon YW
AD  - Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Jeung, Hei-Cheul
AU  - Jeung HC
FAU - Rha, Sun Young
AU  - Rha SY
FAU - Choi, Yeon Ho
AU  - Choi YH
FAU - Yang, Woo Ick
AU  - Yang WI
FAU - Chung, Hyun Cheol
AU  - Chung HC
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20070215
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/*diagnosis/metabolism/mortality/pathology/therapy
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Korea/epidemiology
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/*diagnosis/metabolism/mortality/pathology/therapy
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
EDAT- 2007/06/26 09:00
MHDA- 2007/09/14 09:00
CRDT- 2007/06/26 09:00
PHST- 2006/08/28 00:00 [received]
PHST- 2006/09/01 00:00 [accepted]
PHST- 2007/06/26 09:00 [pubmed]
PHST- 2007/09/14 09:00 [medline]
PHST- 2007/06/26 09:00 [entrez]
AID - 10.1007/s10549-006-9398-2 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2007 Jul;104(1):31-7. doi: 10.1007/s10549-006-9398-2. 
      Epub 2007 Feb 15.